BiotechTube

ARB-001467

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatitis B, Chronic

Conditions

Hepatitis B, Chronic

Trial Timeline

Dec 1, 2015 → May 18, 2018

NCT ID
NCT02631096

About ARB-001467

ARB-001467 is a phase 2 stage product being developed by Arbutus Biopharma for Hepatitis B, Chronic. The current trial status is completed. This product is registered under clinical trial identifier NCT02631096. Target conditions include Hepatitis B, Chronic.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02631096Phase 2Completed

Competing Products

20 competing products in Hepatitis B, Chronic

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
85
peginterferon alfa-2a + rivavirinChugai PharmaceuticalPhase 3
77
SOF + COPEChugai PharmaceuticalPre-clinical
23
Colesevelam HclDaiichi SankyoPhase 2
52
ASP9831 + PlaceboAstellas PharmaPhase 2
52
FK788Astellas PharmaPhase 2
52
MK-2248MerckPhase 1
33
Interferon alfacon-1Astellas PharmaPhase 3
77
Pegylated Interferon + RibavirinAstellas PharmaApproved
85
Tacrolimus + steroids, monoclonal anti-IL2R antibodyAstellas PharmaPhase 2
52
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
33
Dolutegravir + MethadoneShionogiPhase 1
33
Clevudine + AdefovirEisaiPhase 3
77

Other Products from Arbutus Biopharma

VBR + AB-729 + SOC NrtIPhase 2
47
Imdusiran (AB-729)Phase 2
47
Imdusiran + DurvalumabPhase 2
47
AB-729 + Peg-IFNα-2aPhase 2
47
TKM-080301Phase 1/2
36